about
Digital karyotypingTankyrase inhibition stabilizes axin and antagonizes Wnt signallingThe role of chromosomal instability in tumor initiation.Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patientsFacile methods for generating human somatic cell gene knockouts using recombinant adeno-associated virusesGlucose deprivation contributes to the development of KRAS pathway mutations in tumor cellsCrystal structure of human CDK4 in complex with a D-type cyclinChromatid cohesion defects may underlie chromosome instability in human colorectal cancersContribution of polycomb homologues Bmi-1 and Mel-18 to medulloblastoma pathogenesisTargeting cancer with kinase inhibitorsDiscovery and optimization of new benzimidazole- and benzoxazole-pyrimidone selective PI3Kβ inhibitors for the treatment of phosphatase and TENsin homologue (PTEN)-deficient cancersEvaluation of Cancer Dependence and Druggability of PRP4 Kinase Using Cellular, Biochemical, and Structural ApproachesPreparation and optimization of new 4-(morpholin-4-yl)-(6-oxo-1,6-dihydropyrimidin-2-yl)amide derivatives as PI3Kβ inhibitorsDiscovery and optimization of pyrimidone indoline amide PI3Kβ inhibitors for the treatment of phosphatase and tensin homologue (PTEN)-deficient cancersFirst Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway
P50
Q22066241-302873F7-B4FD-41CA-A766-A8053C22E343Q24316697-9B507A31-A652-4B79-BD9D-46C394561504Q24541508-9F98A82A-3E51-4B6F-B6E2-52D65FB3DEA3Q24561669-5E5A63BA-960C-43A0-9452-FDF56FAC4D66Q24633989-417242C3-7825-4299-BF99-8E90DEB8424AQ24648994-DA3CADAB-0314-4C9A-9C8E-CCA91D6D8842Q24656160-4709D09D-941A-49DB-840B-0EA8F4B68536Q24656162-524C3998-D1D8-430B-941E-C23E981FD038Q24675945-730BAD2D-F762-4146-9311-92B6BF5C7F59Q26865765-95668247-C831-434E-933B-0D47B5C17537Q27678653-FDE4E230-7F0B-4D02-9F7A-91C2ABEE64DBQ27679866-528B408E-A1EF-42A1-A87E-A1FC770B7EC1Q27682259-03EC9585-2A19-4525-87E7-A651ED8408FFQ27688061-2335EB61-BEC9-4DFF-AF50-3C2446E90D47Q27698508-BA06023B-F4C2-41D1-81FA-0F73F77EF064
P50
description
onderzoeker
@nl
pharmacologist
@en
name
Christoph Lengauer
@ast
Christoph Lengauer
@en
Christoph Lengauer
@es
Christoph Lengauer
@sl
type
label
Christoph Lengauer
@ast
Christoph Lengauer
@en
Christoph Lengauer
@es
Christoph Lengauer
@sl
prefLabel
Christoph Lengauer
@ast
Christoph Lengauer
@en
Christoph Lengauer
@es
Christoph Lengauer
@sl